YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases

Deng, Yingjian; Li, Guiyang; Chang, Dong; X, Su

doi:10.1016/j.cca.2020.09.035

Cited by 27 publications

(18 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,[32][33][34] It has been reported that YKL-40 could be released by neutrophils, epithelial cells, eosinophils, macrophages, and IL-4 could significantly increase the YKL-40 production in human nasal epithelial cells in vitro. 21,30 More importantly, the expression levels of YKL-40 were positively correlated with the levels of IL-5 and eotaxin in the ovalbumin treated epithelial cells, which were potent chemotactic factors for the recruitment of eosinophils, and promoted recruitment of inflammatory progenitor cells into tissues. 35,36 Although endoscopic sinus surgery bright significantly improved symptoms and quality of life in CRSwNP patients, most patients still suffered a high risk of recurrence.…”

Section: Discussionmentioning

confidence: 95%

“…9,20 YKL-40 has been reported to be involved in the pathogenesis of various inflammatory and allergic diseases such as psoriasis, coronary artery atherosclerotic heart disease, asthma. [21][22][23] Prior studies demonstrated that elevated YKL-40 levels activated dendritic cells and promoted CD4+ T cells polarization, then aggravated airway remodeling in asthma patients. [24][25][26][27] A recent study demonstrated that inhibition of the YKL-40 gene expression in asthmatic mice could alleviate eosinophilic airway inflammation, airway hyperreactivity, airway mucus secretion and significantly reduce the mRNA levels of IL-5, IL-13 and eotaxin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum YKL-40 Levels Predict Endotypes and Associate with Postoperative Recurrence in Patients with Chronic Rhinosinusitis with Nasal Polyps

Wen¹,

Cheng²,

Xie³

et al. 2021

JAA

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Serum YKL-40 Levels Predict Endotypes and Associate with Postoperative Recurrence in Patients with Chronic Rhinosinusitis with Nasal Polyps

Wen¹,

Cheng²,

Xie³

et al. 2021

JAA

View full text Add to dashboard Cite

Section: Biomarkers In Psoriasis Treatmentmentioning

confidence: 99%

“…Chitinase-3 -like 1, also known as YKL-40, is a glycoprotein that contains highly conserved chitin-binding domains without chitinase activity [ 181 , 182 , 183 ]. YKL-40 is secreted by various immune cells, such as neutrophils and macrophages, fibroblasts, vascular smooth muscle cells, and endothelial cells [ 181 , 182 , 183 ]. YKL-40 expression is upregulated by proinflammatory cytokines, namely IL-6, TNF, IL-13, and IL-18, and is associated with tumor progression, angiogenesis, and various inflammatory responses [ 181 , 182 , 183 ].…”

Section: Biomarkers In Psoriasis Treatmentmentioning

confidence: 99%

“…YKL-40 is secreted by various immune cells, such as neutrophils and macrophages, fibroblasts, vascular smooth muscle cells, and endothelial cells [ 181 , 182 , 183 ]. YKL-40 expression is upregulated by proinflammatory cytokines, namely IL-6, TNF, IL-13, and IL-18, and is associated with tumor progression, angiogenesis, and various inflammatory responses [ 181 , 182 , 183 ]. In psoriatic lesions, YKL-40 expression is detected in infiltrating neutrophils, and serum YKL-40 levels are significantly more elevated in cases of generalized pustular psoriasis compared to cases of plaque-type psoriasis [ 184 ].…”

Section: Biomarkers In Psoriasis Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity

Honma

Nozaki

2021

JCM

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease induced by multifactorial causes and is characterized by bothersome, scaly reddish plaques, especially on frequently chafed body parts, such as extensor sites of the extremities. The latest advances in molecular-targeted therapies using biologics or small-molecule inhibitors help to sufficiently treat even the most severe psoriatic symptoms and the extra cutaneous comorbidities of psoriatic arthritis. The excellent clinical effects of these therapies provide a deeper understanding of the impaired quality of life caused by this disease and the detailed molecular mechanism in which the interleukin (IL)-23/IL-17 axis plays an essential role. To establish standardized therapeutic strategies, biomarkers that define deep remission are indispensable. Several molecules, such as cytokines, chemokines, antimicrobial peptides, and proteinase inhibitors, have been recognized as potent biomarker candidates. In particular, blood protein markers that are repeatedly measurable can be extremely useful in daily clinical practice. Herein, we summarize the molecular mechanism of psoriasis, and we describe the functions and induction mechanisms of these biomarker candidates.

show abstract

Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months

Wel

Schaepdryver

Poesen

et al. 2022

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective To investigate biomarkers of disease progression in cerebrospinal fluid (CSF) and serum in adult patients with spinal muscular atrophy (SMA). Furthermore, we assess the clinical response to nusinersen treatment in adults with SMA over a longer follow‐up period than the previously reported 6–14 months. Methods We included 16 adults with SMA type 3–4 for nusinersen treatment over 22 months in this prospective study. We evaluated chitotriosidase‐1 (CHIT1) and chitinase‐3‐like protein 1 (YKL‐40) as neuroinflammatory biomarkers in CSF, and neurofilament light chain (NfL) and heavy chain (pNfH) as neurodegenerative markers in CSF and serum at baseline, month 6, 14 and 22, together with a wide range of clinical outcome measures. Results Levels of CHIT1 increased significantly (p = 0.048) throughout the 22‐month treatment period and pNfH decreased significantly (p = 0.022) in CSF, but both did not correlate with clinical outcome measures. YKL‐40 correlated strongly with neurofilaments in CSF (rho = 0.76) and decreased significantly (p = 0.037) in patients with improvements in the revised upper limb module (RULM). Finally, patients showed significant improvements in hand grip strength, hand motor function, medical research council (MRC) sum score, and peak expiratory flow (PEF) after 22 months of treatment. Interpretation YKL‐40 in CSF correlated with clinical improvements during nusinersen treatment. In contrast, CHIT1 and pNfH in CSF changed significantly during treatment but did not correlate with clinical outcomes. Finally, we demonstrated a sustained clinical effect of nusinersen treatment in adults after 22 months.

show abstract

YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases

Cited by 27 publications

References 88 publications

Serum YKL-40 Levels Predict Endotypes and Associate with Postoperative Recurrence in Patients with Chronic Rhinosinusitis with Nasal Polyps

Serum YKL-40 Levels Predict Endotypes and Associate with Postoperative Recurrence in Patients with Chronic Rhinosinusitis with Nasal Polyps

Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity

Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months

Contact Info

Product

Resources

About